Great West Life Assurance Co. Can Boosts Stock Position in DexCom, Inc. (NASDAQ:DXCM)

Great West Life Assurance Co. Can increased its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 8.1% during the second quarter, HoldingsChannel reports. The institutional investor owned 294,714 shares of the medical device company’s stock after acquiring an additional 22,150 shares during the period. Great West Life Assurance Co. Can’s holdings in DexCom were worth $38,072,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in DXCM. Avalon Trust Co acquired a new stake in shares of DexCom in the first quarter valued at about $26,000. Atlas Capital Advisors LLC acquired a new position in shares of DexCom in the 2nd quarter valued at $33,000. TFC Financial Management Inc. boosted its stake in DexCom by 4,814.3% during the first quarter. TFC Financial Management Inc. now owns 344 shares of the medical device company’s stock worth $40,000 after buying an additional 337 shares during the period. Valley National Advisers Inc. boosted its position in shares of DexCom by 33.5% during the 2nd quarter. Valley National Advisers Inc. now owns 379 shares of the medical device company’s stock worth $49,000 after purchasing an additional 95 shares during the period. Finally, Center for Financial Planning Inc. purchased a new stake in DexCom in the second quarter valued at approximately $51,000. Hedge funds and other institutional investors own 93.88% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the company. Canaccord Genuity Group lifted their price objective on DexCom from $135.00 to $150.00 and gave the company a “buy” rating in a research note on Friday, July 28th. Robert W. Baird cut their price target on shares of DexCom from $153.00 to $130.00 and set an “outperform” rating on the stock in a research note on Monday, August 21st. Leerink Partnrs reissued an “outperform” rating on shares of DexCom in a research note on Monday, October 16th. TheStreet downgraded shares of DexCom from a “b-” rating to a “c+” rating in a research note on Wednesday, September 6th. Finally, Barclays raised their price target on shares of DexCom from $115.00 to $138.00 and gave the company an “equal weight” rating in a research report on Monday, July 31st. Three analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, DexCom currently has a consensus rating of “Moderate Buy” and a consensus price target of $130.93.

DexCom Stock Performance

Shares of DexCom stock opened at $108.96 on Tuesday. The company has a quick ratio of 2.50, a current ratio of 2.80 and a debt-to-equity ratio of 1.07. DexCom, Inc. has a 52 week low of $74.75 and a 52 week high of $139.55. The firm’s 50 day moving average is $91.06 and its two-hundred day moving average is $109.71. The firm has a market capitalization of $42.10 billion, a P/E ratio of 119.74, a P/E/G ratio of 2.13 and a beta of 1.13.

DexCom (NASDAQ:DXCM) last posted its earnings results on Thursday, October 26th. The medical device company reported $0.50 EPS for the quarter, beating analysts’ consensus estimates of $0.34 by $0.16. DexCom had a net margin of 11.08% and a return on equity of 25.05%. The firm had revenue of $975.00 million for the quarter, compared to the consensus estimate of $939.64 million. During the same period last year, the firm posted $0.28 EPS. The company’s revenue was up 26.7% on a year-over-year basis. Research analysts forecast that DexCom, Inc. will post 1.43 EPS for the current fiscal year.

Insider Buying and Selling at DexCom

In other news, Director Steven Robert Pacelli sold 411 shares of the business’s stock in a transaction that occurred on Wednesday, August 23rd. The stock was sold at an average price of $107.03, for a total value of $43,989.33. Following the transaction, the director now owns 126,008 shares of the company’s stock, valued at $13,486,636.24. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In other news, Director Steven Robert Pacelli sold 411 shares of the firm’s stock in a transaction on Wednesday, August 23rd. The stock was sold at an average price of $107.03, for a total value of $43,989.33. Following the completion of the transaction, the director now owns 126,008 shares in the company, valued at $13,486,636.24. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, EVP Barry J. Regan sold 2,019 shares of the stock in a transaction on Wednesday, November 8th. The shares were sold at an average price of $95.22, for a total value of $192,249.18. Following the sale, the executive vice president now owns 64,250 shares in the company, valued at approximately $6,117,885. The disclosure for this sale can be found here. Over the last quarter, insiders sold 6,908 shares of company stock worth $657,820. 0.41% of the stock is owned by insiders.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.